Why the study?
Does the choice of oral anticoagulant (dabigatran, rivaroxaban, or apixaban) affect the rates of deep vein thrombosis and postoperative hematomas in patients undergoing large joint arthroplasty?
Cohort (n=10,241)
Does the choice of oral anticoagulant (dabigatran, rivaroxaban, or apixaban) affect the rates of deep vein thrombosis and postoperative hematomas in patients undergoing large joint arthroplasty?
Dabigatran may provide a more favorable efficacy and safety profile for thromboprophylaxis following large joint arthroplasty compared to rivaroxaban and apixaban.
Dabigatran may be considered for post-arthroplasty thromboprophylaxis; observational data leave open the need for randomized confirmation.
No takes yet. Share an insight, caveat, or question.
Фирсов et al. (2015) conducted a cohort in Large joint arthroplasty (total knee or total hip) (n=10,241). Dabigatran vs. Rivaroxaban and Apixaban was evaluated on Clinically significant deep vein thrombosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: